Jesus Leal Email and Phone Number

P&L responsibilities for a $1.8 Billion Franchise that includes Xolair, TOBI and the COPD portfolio. BD&L, Strategy and LCM across Novartis Pharmaceuticals Corporation.

Launched TOBI Podhaler and achieved 200% to target in the launch year despite new branded competitors and generic entry to TOBI solution.Prepared launch plans for Serelaxin for Acute Heart Failure

Integration of Medical and Commercial Strategies early in the product lifecycle to ensure asset maximization. Collaborate with NIBR, clinical development, medical, regulatory, legal and commercial to optimize short and long term opportunities. Develop BD&L strategies, identify and evaluate opportunities consistent with that strategy. Optimize Patient Access and Brand Value Proposition through the execution of scientifically sound HEOR projects.

Consulting services for Pharma/Biotech companies. Launch strategies, Go-To-Market Models, hyper-competitive markets, Systems of Care, Sales and Marketing Execution Excellence. Current projects in cardiac monitoring, cardiovascular diseases, liver diseases, allergic disorders and rare diseases. Projects include marketed products as well as multiple development stage assets backed by private funding and/investment firms.

Same as other VP role at Novartis

General Management responsibilities. Launched the #1 prescribed RX product sold in the US, ProAir HFA. Product launch was perhaps one of the most innovative launches ever in the industry. Tripled sales of the respiratory franchise in 2 years products included ProAir HFA, QVar, Nasarel.

General Management, Sales, Marketing, Medical etc

Executive Director, Sales and Sales Operations